Arch Biopartners Inc (V:ARCH) — Market Cap & Net Worth
Market Cap & Net Worth: Arch Biopartners Inc (ARCH)
Arch Biopartners Inc (V:ARCH) has a market capitalization of $43.74 Million (CA$60.46 Million) as of September 17, 2026. Listed on the V stock exchange, this Canada-based company holds position #22490 globally and #803 in its home market, demonstrating a -12.75% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arch Biopartners Inc's stock price CA$0.89 by its total outstanding shares 67933289 (67.93 Million). Also see Arch Biopartners Inc balance sheet assets for a full breakdown of the balance sheet.
Arch Biopartners Inc Market Cap History: 2015 to 2026
Arch Biopartners Inc's market capitalization history from 2015 to 2026. Data shows growth from $15.73 Million to $43.74 Million (8.51% CAGR). Also see Arch Biopartners Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Arch Biopartners Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arch Biopartners Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Arch Biopartners Inc (ARCH) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
36.66x
Arch Biopartners Inc's market cap is 36.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $47.67 Million | $93.88K | -$2.36 Million | 507.77x | N/A |
| 2020 | $73.22 Million | $67.89K | -$4.63 Million | 1078.59x | N/A |
| 2021 | $169.54 Million | $3.89 Million | -$1.17 Million | 43.62x | N/A |
| 2022 | $138.09 Million | $964.68K | -$1.39 Million | 143.14x | N/A |
| 2023 | $72.73 Million | $1.98 Million | -$3.33 Million | 36.66x | N/A |
Competitor Companies of ARCH by Market Capitalization
Companies near Arch Biopartners Inc in the global market cap rankings as of September 17, 2026. Review ARCH tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Arch Biopartners Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Arch Biopartners Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Arch Biopartners Inc's market cap moved from $15.73 Million to $ 43.74 Million, with a yearly change of 8.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$43.74 Million | -27.05% |
| 2025 | CA$59.95 Million | -36.79% |
| 2024 | CA$94.84 Million | +30.41% |
| 2023 | CA$72.73 Million | -47.33% |
| 2022 | CA$138.09 Million | -18.55% |
| 2021 | CA$169.54 Million | +131.54% |
| 2020 | CA$73.22 Million | +53.61% |
| 2019 | CA$47.67 Million | -25.95% |
| 2018 | CA$64.38 Million | +184.78% |
| 2017 | CA$22.61 Million | +13.58% |
| 2016 | CA$19.90 Million | +26.56% |
| 2015 | CA$15.73 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Arch Biopartners Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $43.74 Million USD |
| MoneyControl | $43.74 Million USD |
| MarketWatch | $43.74 Million USD |
| marketcap.company | $43.74 Million USD |
| Reuters | $43.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related … Read more